Japan· JP-4291046M1020
ダブラフェニブメシル酸塩
A dabrafenib product containing ダブラフェニブメシル酸塩, registered in Japan by ノバルティス ファーマ, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Dabrafenib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EC02 (dabrafenib), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 8 of them publish a price we can compare per daily dose
Dabrafenib · ATC L01EC02
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of dabrafenib costs, country by country.
Normalised to the WHO defined daily dose (0.3 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Dabrafenib · price per daily dose (0.3 g)
USD · FX 28 Sept 2026
- CH Switzerland$232.39
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ダブラフェニブメシル酸塩
- Manufacturer
- ノバルティス ファーマ
- Country
- Japan (JP)
- ATC code
- L01EC02
- ATC class
- Dabrafenib
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
522 interactions on record for dabrafenib.
Graded by severity as the source publishes them — 79 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Dabrafenib · interactions on record
522 records
- 79 severe
- 430 moderate
- 13 minor
Most severe, free to view
- LonafarnibA16AX20severe
- AvatrombopagB02BX08severe
- VoxelotorB06AX03severe
- RanolazineC01EB18severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01EC02
Dabrafenib, as other registers publish it.
- IcelandFinleeNovartis Europharm Limited*
- NorwayFinleeNovartis Europharm Limited
- DenmarkFinleeNovartis Europharm Limited
- FinlandFinleeNovartis Europharm Limited
- PolandFinleeNovartis Europharm Limited
- CzechiaFINLEENovartis Europharm Limited, Dublin
- CzechiaFINLEENovartis Europharm Limited, Dublin
- BelgiumFinlee 10 mgNovartis Europharm
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ffcc22b2-b172-4222-b452-b8008dec6dd0 GET /v1/drugs/ffcc22b2-b172-4222-b452-b8008dec6dd0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "５０ｍｇ１カプセル",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4291046M1020",
"category": "内用薬",
"price_yen": 5367.7,
"generic_name": "ダブラフェニブメシル酸塩",
"product_name_jp": null,
"therapeutic_class": "4291",
"transitional_expiry": null
}See everything about dabrafenib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.